Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has appointed Dr. Balaji V. Prasad as Chief Strategy Officer. Dr. Prasad brings 25 years of pharmaceutical industry experience, combining medical expertise with financial analysis background.
Most recently serving as a director and equities analyst at Barclays, Dr. Prasad covered US specialty pharma with Alvotech in his portfolio. His previous roles include portfolio manager at a Swiss asset management firm and leadership positions at Barclays and Goldman Sachs India healthcare coverage. He holds an MD from Bangalore Medical College and MBA from IIM Ahmedabad.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale focalizzata sullo sviluppo di medicinali biosimilari, ha nominato Dr. Balaji V. Prasad come Chief Strategy Officer. Il Dr. Prasad porta con sé 25 anni di esperienza nell'industria farmaceutica, combinando competenze mediche con una solida esperienza in analisi finanziaria.
Recentemente ha ricoperto il ruolo di direttore e analista di azioni presso Barclays, dove ha seguito il settore farmaceutico specializzato negli Stati Uniti, incluso Alvotech nel suo portafoglio. Le sue esperienze precedenti includono quella di gestore di portafoglio in una società di gestione patrimoniale svizzera e posizioni di leadership presso Barclays e Goldman Sachs per la copertura del settore sanitario in India. Ha conseguito un MD presso il Bangalore Medical College e un MBA presso l'IIM Ahmedabad.
Alvotech (NASDAQ: ALVO), una compañía biotecnológica global centrada en el desarrollo de medicamentos biosimilares, ha nombrado a Dr. Balaji V. Prasad como Director de Estrategia. El Dr. Prasad aporta 25 años de experiencia en la industria farmacéutica, combinando experiencia médica con un sólido trasfondo en análisis financiero.
Recientemente, se desempeñó como director y analista de acciones en Barclays, donde cubrió la farmacéutica especializada de EE. UU., incluyendo a Alvotech en su cartera. Sus roles anteriores incluyen el de gerente de cartera en una firma de gestión de activos suiza y posiciones de liderazgo en Barclays y Goldman Sachs en la cobertura del sector salud en India. Tiene un MD del Bangalore Medical College y un MBA del IIM Ahmedabad.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 주력하는 글로벌 생명공학 회사로, Dr. Balaji V. Prasad를 최고 전략 책임자로 임명했습니다. Prasad 박사는 25년의 제약 산업 경험을 가지고 있으며, 의료 전문성과 재무 분석 배경을 결합하고 있습니다.
최근 Barclays에서 이사 및 주식 분석가로 재직하며 Alvotech을 포트폴리오에 포함한 미국 전문 제약 분야를 다루었습니다. 그의 이전 역할에는 스위스 자산 관리 회사의 포트폴리오 관리자와 Barclays 및 Goldman Sachs 인도 헬스케어 부문의 리더십 직책이 포함됩니다. 그는 Bangalore Medical College에서 의학 박사(MD)를, IIM Ahmedabad에서 MBA를 취득했습니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale axée sur le développement de médicaments biosimilaires, a nommé Dr. Balaji V. Prasad au poste de directeur de la stratégie. Le Dr. Prasad apporte 25 ans d'expérience dans l'industrie pharmaceutique, alliant expertise médicale et expérience en analyse financière.
Dernièrement, il a occupé le poste de directeur et d'analyste des actions chez Barclays, où il a suivi le secteur pharmaceutique spécialisé aux États-Unis, incluant Alvotech dans son portefeuille. Ses précédents postes incluent celui de gestionnaire de portefeuille dans une société de gestion d'actifs suisse et des postes de direction chez Barclays et Goldman Sachs pour la couverture du secteur de la santé en Inde. Il est titulaire d'un MD du Bangalore Medical College et d'un MBA de l'IIM Ahmedabad.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf die Entwicklung von biosimilaren Arzneimitteln konzentriert, hat Dr. Balaji V. Prasad zum Chief Strategy Officer ernannt. Dr. Prasad bringt 25 Jahre Erfahrung in der Pharmaindustrie mit, wobei er medizinisches Fachwissen mit einem Hintergrund in Finanzanalyse kombiniert.
Zuletzt war er als Direktor und Aktienanalyst bei Barclays tätig, wo er den US-Spezialpharmasektor mit Alvotech in seinem Portfolio abdeckte. Zu seinen früheren Positionen gehören Portfoliomanager bei einer Schweizer Vermögensverwaltungsgesellschaft sowie Führungspositionen bei Barclays und Goldman Sachs im Bereich Gesundheitsversorgung in Indien. Er hat einen MD vom Bangalore Medical College und einen MBA von der IIM Ahmedabad.
- Appointment of CSO with dual expertise in medicine and financial markets
- New CSO brings established relationships across investment community
- CSO already familiar with company's operations through previous analyst coverage
- None.
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer.
A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously as portfolio manager at a Swiss asset management firm focusing on global specialty pharma and generics and led Barclays' and Goldman Sachs' India healthcare coverage from Mumbai. He earned his MD from Bangalore Medical College and MBA from IIM Ahmedabad.
"It is a great pleasure to welcome Balaji onboard not only as a new member of the team, but one who has closely followed our growth and the evolution of our business and product pipeline," said Róbert Wessman, chairman and CEO of Alvotech. "He will be able to hit the ground running, helping to advance the business with his own expertise at the interface of medicine and therapeutics, and through his excellent relationships across the investment community."
"Alvotech is one of the most innovative and important companies in this critical space, and I am truly thrilled to be joining a company I have followed and admired," said Dr Prasad. "As a doctor and analyst of this space, I believe that biosimilars are key to delivering many of the amazing medicines that exist today to all of the people who need them. Alvotech is an incredibly exciting and focused business, and I will be putting my all into communicating the value of what we are doing to our growing circle of stakeholders in the US and globally - so we can deliver for patients and investors alike. I aim to bring my diverse experience across multiple continents and network encompassing the pharmaceutical, asset management and investment banking industries to drive Alvotech's goal of expanding affordable biologics globally"
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
What is Dr. Balaji V. Prasad's background before joining Alvotech (ALVO) as CSO?
What are Dr. Prasad's qualifications and educational background for the ALVO CSO position?
How will Dr. Prasad's appointment benefit Alvotech's (ALVO) strategic direction?
What is Dr. Prasad's vision for his role at Alvotech (ALVO)?
